| Literature DB >> 30854333 |
Khalid O Alfarouk1,2,3,4, Adil H H Bashir2,5, Ahmed N Aljarbou6,7, AbdelRahman M Ramadan8, Abdel Khalig Muddathir2,9, Sari T S AlHoufie3,10, Abdelhamid Hifny11, Gamal O Elhassan12, Muntaser E Ibrahim5, Saad S Alqahtani13, Shakir D AlSharari14,15, Claudiu T Supuran16, Cyril Rauch17, Rosa Angela Cardone18, Stephan J Reshkin18, Stefano Fais19, Salvador Harguindey20.
Abstract
Helicobacter pylori (HP) is a facultative anaerobic bacterium. HP is a normal flora having immuno-modulating properties. This bacterium is an example of a microorganism inducing gastric cancer. Its carcinogenicity depends on bacteria-host related factors. The proper understanding of the biology of HP inducing gastric cancer offers the potential strategy in the managing of HP rather than eradicating it. In this article, we try to summarize the biology of HP-induced gastric cancer and discuss the current pharmacological approach to treat and prevent its carcinogenicity.Entities:
Keywords: Helicobacter pylori; gastric cancer; inflammation; pH; pharmacology
Year: 2019 PMID: 30854333 PMCID: PMC6395443 DOI: 10.3389/fonc.2019.00075
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1A model that represents the H. pylori—host’s eicosanoids interactions.
Shows some factors that govern H. pylori—human (host) that mediates carcinogenesis.
| Urease | Beta-catenin |
| Carbonic Anhydrase | |
| VacA | |
| CagA | EGFR |
| Lewis Antigen | |
| BabA2 |